This round is no longer accepting investments, but hundreds just like it are live now.

Log In


Building families through science

We believe PherDal is the only sterile, patent-pending, at-home insemination kit out there. Our goal is to provide access to safe and affordable fertility options backed by science. While we are pre-revenue, we have established the trademark for “Pherdal” and our proof-of-concept kits sold out in just 90 days and helped others conceive. We anticipate having a product on the market by the end of 2022.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$633,530.44 Raised

Reasons to Invest

  • Developing the first FDA-cleared, sterile, patent-pending, assisted reproduction kit as an affordable, over-the-counter fertility option.
  • The Fertility Treatment Market size is valued at $14.27 billion in 2020 and is expected to reach $21.7 billion by 2025 (source).

  • Invented & led by Northern Illinois University’s first recipient of a doctoral degree in bioinformatics, whose clinical research has been cited over 500 times by peers, and was most recently Director of Product for a 15M+ revenue SaaS company. 

(source, source, source, source, source, source, source)


Empowering people to take control of their fertility journey

Here at PherDal, we aim to provide a science-based, safe, sterile, and affordable fertility option - all in the privacy of your own home. 

(source, source, source, source, source)

In addition to making the fertility journey less invasive, we feel we are a source of support for the LGBTQAI+ community, single parents by choice, and people struggling with infertility. With that, we believe Pherdal offers the only patent-pending, sterile, at-home intracervical insemination kit.  

Founded by a couple who has experienced infertility themselves - our company genuinely understands the hurt, frustration, and pain of trying to conceive. After Dr. Jenn and her husband created PherDal, they conceived their first child in the second month of use. It gave them hope that they could help others as well. 

The Problem

1 in 5 women have difficulty conceiving after one year of trying

An additional 1 in 4 have difficulty carrying a pregnancy to term (source). On top of that, many people also struggle to even afford the services fertility clinics offer (source). The need for assisted reproduction technology is growing at a rate of 5-10% per year to meet the demand of increased infertility (source). We think people need access to safe, sterile fertility options to try in the privacy of their own homes - especially before trying more invasive measures.

(source, source, source, source, source, source, source, source)

Intrauterine Insemination, or IUI, is often the first line of fertility treatment and is performed in a sterile environment at a fertility clinic (source, source).  However, there is a lesser-known form of artificial insemination called Intracervical Insemination or ICI that can be a great first-line of fertility treatment too (source).  A 2015 study showed ICI, like the PherDal kit offers, and IUI have the same live birth rate over a 6 month time period in medicated and natural ovulation cycles (source). Similar results were found in a 2018 study (source). 

However, we believe our ICI kit is the first to combine the sterile environment of the fertility clinic with the at home capabilities of artificial insemination.  When it comes to the importance of sterile environments for infertility treatments, a 2017 study showed that women diagnosed with idiopathic (or unknown) infertility were proven to have a significant differentiation in the proportion of 3 bacterial species naturally present in the vaginal microbiome (source, source). Since then, there has continued to be more scientific research published about the role the microbiome plays in infertility. So much so that a 2020 review of clinical practice recommendations for fertility specialists called the vaginal microbiome the “new frontier” that would increase the overall knowledge of reproductive health (source).

Therefore, we believe we’re bridging the gap between traditional conception and more invasive options with a sterile ICI option for couples facing infertility, including male factor infertility, single mothers by choice, and the LGBTQ+ community. 

*The above is an image of a  proof of concept kit. Final future product is still currently under development and is not yet available on the market.

The Solution

Safe, sterile, at-home fertility option for everyone

We are looking to make safe and sterile at-home insemination possible. That’s why PherDal at-home insemination kits are designed to be able to deliver the sperm closer to the egg, potentially bypassing any bacterial or anatomical interference.

(source, source, source, source, source, source, source, source

We feel that PherDal is leading the industry by including 3 sterile syringes and 3 cups, per kit. That means more chances per month at less cost -  without reusing anything.

We feel our business model is similar to at-home, over-the-counter, pregnancy tests.  But what we think makes us unique is what we see as our unestablished market. We don’t think enough people know that sterile Intracervical insemination (ICI) is an option to try before Intrauterine insemination (IUI) - as a safe, affordable, way to try and build families.


The Market

The fertility treatment market is growing 

The Fertility Treatment Market size is valued at $14.27 billion in 2020 and is expected to reach $21.7 billion by 2025 (source).

Not to mention, almost two-thirds (64%) of couples trying to get pregnant have tried alternative or natural remedies to conceive (source).

We have found a new  industry containing an estimated 12.2 million people struggling to conceive each year (source). PherDal has the potential to offer these people a method of artificial insemination option that we feel is safe, sterile, and private - and we think we are the only ones doing so. 

(source, sourcesourcesourcesource*The above is an image of a proof of concept kit. Final future product is still currently under development and is not yet available on the market.

Our Traction

PherDal's conception and progress

Here’s our timeline of how our founders overcame unexplained infertility, and how PherDal helped: 

While PherDal started as the founder’s story, our proof of concept kit launched last year - selling out in 90 days. Most importantly, we believe PherDal helped others successfully conceive too. We have now set a goal to be the only FDA-cleared insemination kit offered over-the-counter as a safe and sterile fertility option. 

Why Invest

We intend to offer the first over the counter assisted reproduction catheter to the growing  infertility space

And to us, success is giving people the potential to feel hope on their fertility journey. 

In the next 3-5 years, we anticipate PherDal being available in local pharmacies across North America and Europe - potentially providing a safe, sterile option for everyone.

We have already engaged with the United States FDA to initiate the premarket submission process. And with that, we anticipate having PherDal cleared via 510(k) premarket notification by the end of 2022.

Once manufacturing is scaled, we anticipate our PherDal kits to sell for less than $149 with a direct-to-consumer unit gross margin of in excess of 75%. 

We believe our patent is on track to be awarded this fall, putting us in the position, we feel, to potentially disrupt the 2023 market with our anticipated, patented, FDA-cleared, OTC medical device. 

(source, source, source, source, source, source, source, source)

*The above is an image of a proof of concept kit. Final future product is still currently under development and is not yet available on the market


405 W 2ND ST UNIT 1141
DIXON, IL 61021

We believe PherDal is the only sterile, patent-pending, at-home insemination kit out there. Our goal is to provide access to safe and affordable fertility options backed by science. While we are pre-revenue, we have established the trademark for “Pherdal” and our proof-of-concept kits sold out in just 90 days and helped others conceive. We anticipate having a product on the market by the end of 2022.


Dr. Jennifer Hintzsche, Ph.D.
Dr. Jennifer Hintzsche, Ph.D.
Chief Executive Officer

Dr. Jenn is a wife, mother, innovator, and passionate advocate for women’s health. Hintzsche was Northern Illinois University’s first recipient of a doctoral degree in bioinformatics (a field of study that combines computer science and biology) in 2014 after obtaining a Master's Degree in the same subject. She earned her BA in Biochemistry from Augustana College. She is the author of over two-dozen peer-reviewed scientific articles and her work has been cited nearly 500 times in respected science journals for her clinical expertise.

Dr. Jenn was diagnosed with unexplained infertility in 2017 and was told expensive fertility options were her only chance at conceiving. Hintzsche and husband Ryan invented and conceived their daughter using their patent-pending PherDal kit. PherDal is the only sterile at-home insemination kit that has already helped over a dozen women conceive. PherDal is located in Dixon, IL and is registered with the FDA as an over the counter medical device.  




It is an exciting time to be a physician in Industry. I am always learning, and cherish the opportunity to collaborate with talented people in all areas of medical affairs, regulatory, research, and medical education, making a global impact on women’s health! I of course miss and always will miss the privilege to be 1:1 with patients. I was so lucky to have opportunities and experiences as an OB/GYN in private practice /MIS, in academics, and as a hospitalist. 

Experienced in:

Medical Device Development and Strategy, Marketing and VOC

FDA and EU MDA experience in CER, CEP and PFCP and COPA 

Medical Affairs, Regulatory, Payors , Pharmacovigilance, Medical Education, Device Proctoring, and Medical Marketing and HEOR, PMRP, Good Clinical Practice. Clinical Trail Oversight and Onboarding as well as protocol development. VEEVA, Medra, AGILE, Scrum, and Oracle & Teams experience. Individual career transition coaching. Cross-functional team player. Consulting on non-clinical career transition for physicians. Patient Journey, Payer Ad Board Development. Evidence Generation, GCP, Clinical Research Oversight, Onboarding, and Protocol development. ACOOG gov affairs committee -post. PESC- Graduate Education Review committee - post. Girls Experiencing Medical Science mentor ( Gems) girl-scout camp.

Dr. Steven R. Lindheim, M.D., M.M.M.

Dr. Steven R. Lindheim, M.D., M.M.M.

Medical Advisor

Dr. Lindheim is a Professor of Obstetrics and Gynecology at both Wright State University, Boonshoft School of Medicine in Dayton, Ohio and the University of Central Florida in Orlando, Florida, as well as Visiting Professor of Shanghai Jiao Tong University School of Medicine in Shanghai, China. He graduated from Temple School of Medicine and was a resident at Pennsylvania Hospital in Philadelphia. Dr. Lindheim completed a fellowship in Reproductive Endocrinology and Infertility at the University of Southern California, his Masters in Medical Management from Tulane University, School of Public Health and Tropical Medicine, and is currently Board Certified in both Ob/Gyn and Reproductive Endocrinology and Infertility. He previously served on as the Board of Directors for ASRM and is Past President for the Society of Reproductive Surgeons. Dr. Lindheim has a major interest in In vitro fertilization, oocyte donation, embryo donation and surrogacy. He is a well-recognized expert in the field of minimally invasive reproductive surgery and has over 250 scientific publications, and book chapters and is Associate Editor for Fertility Sterility. His research focuses upon embryo implantation, minimally invasive reproductive surgery, and Polycystic Ovarian Syndrome (PCOS). 

Dr. Rhonda Alexander

Dr. Rhonda Alexander

Chief Regulatory Officer

Dr. Rhonda Alexander is a global entrepreneur, speaker, coach, and author. She is the founder of IUVO Consulting, LLC, an international regulatory-compliance consulting firm, and E2 Entrepreneur & Executive Coaching, LLC, a firm dedicated to facilitating the growth and development of entrepreneurs and leaders. 

In addition to authoring three books: EntrHERpreneur, Your Life’s Calling, and Side-Hustle or Sustainable, Dr. Rhonda has worked with organizations and professionals around the world. As a result, she has garnered more than 25 years of unique experiences that make her a creative organizational strategist, as well as an inspired, compassionate, and driven speaker and coach. 

Dr. Rhonda is the mother of Maiyah, an amazing young woman, who is the joy and pride of her life. 

Kristin Perez

Kristin Perez

Chief Marketing Officer

Kristin Perez is the owner of Unplug Marketing which first established PherDal's social media presence in late 2021. Kristin enjoys using her social media skills to contribute to the success of small businesses. She has been in the marketing industry, and specifically social media for over 15 years. 

In her free time, Kristin likes to hike and spend time with her husband and two-year-old daughter. 

Makeva Phelps

Makeva Phelps

Chief Operations Officer

With over 25 years of various pharmacy, account management, audit and operations experience, Makeva collaborates with executive leadership, internal and external clients to define long-term goals and identify ways to support the clients mission. Makeva's primary focus is process improvement, efficiency, and training and development. Makeva is a strategic, innovative, and results driven leader committed to partnering with business stakeholders to improve performance and drive results. Makeva is dedicated to enhancing customer and client engagement and fostering a culture that supports the overall business objectives. Prior to joining the Pherdal Executive board, Makeva held roles as a Client Experience Manager, Operations Manager, and Benefits Auditor. Makeva holds a B.S. Business Forensics from Franklin University and B.A. Business Administration from University of Phoenix. 

*Currently on extended bereavement leave, return date TBD*

Tessa Mills

Tessa Mills

Advisor, Brain-based coach + fertility doula for women

Hey friend! I’m Tessa Mills, the second PherDal momma as well as a brain-based coach, fertility doula and bodyworker.

I’ll help you understand how your mind-body machine works, use intuitive questioning to help you uncover your own answers and teach you self-care tools that fuel your journey to creating the life you desire. 

When I say “self-care”, I’m not talking about expensive spa treatments or bubble baths (although those feel pretty damn good once in awhile!). 

I’m talking about self-care tools that help you 1) become aware of the thoughts making you feel like shit and 2) Re-wire your thinking to calm your nervous system and fuel the most evolved parts of your brain (i.e. So you can  

So whether you want to take charge of your reproductive health and fertility, discover the courage to leave a toxic relationship, or simply create a soul-affirming life that has you jumping out of bed before the sun comes up, I’ll guide you there with fun, effective and science-based tools and strategies.

Ryan Westphal

Ryan Westphal

Chief Engineer & Secretary of the Board

Ryan Westphal has 15+ years of engineering experience in the automotive and aerospace industries. Over the last 10+ years, he has been focused on the development of emissions devices such as heat exchangers, rotary electric valves and actuators. Ryan currently brings his breadth of experience and leadership in new product launch to a team of engineers, designers and technicians working with the major commercial vehicle and passenger car OEM’s in North America.

Ryan received his Bachelor of Science in Mechanical Engineering from Northern Illinois University in 2008 and resides in Dixon, IL with his wife Jenn and children Lois and Zack. In his free time he is an avid Chicago Bears fan, enjoys tinkering on his car and advancing his 3D printing skills.

Matthew Croll

Matthew Croll

Chief Financial Officer

Matt Croll has nearly 30 years of finance experience including more than 15 years a CFO. He has worked with a variety of companies in manufacturing, distribution, consumer products, agriculture, and professional services. Matt brings a multi-faceted view to business opportunities and a strong analytical perspective to business decisions. He founded Vector CFO in 2014. Vector CFO delivers fractional CFO services to companies that have needs best served by a seasoned CFO but who lack the scale to require a full-time CFO. During his career, Matt has evaluated dozens of M&A opportunities and executed more than 25 acquisitions or divestitures of businesses. He has also served as CFO during periods of rapid growth within companies. Matt received his BS in Accountancy from the University of Illinois and his MBA from Northwestern University. He is a registered CPA. Matt resides in Naperville, IL with his wife and two daughters. He enjoys staying active and participating in various sports in his spare time.

David Hintzsche

David Hintzsche

Chairman of the Board

David Hintzsche was part of the team who grew a family-owned agri-business into a company. For 42 years, he had a successful career with many titles at Hintzsche Fertilizer, Inc., in Illinois. The business grew with over 150 million in sales, 225 employees at 15 ag retail locations, and many contract pork production sites in northern Illinois and eastern Iowa. He is also the grandfather of the first PherDal baby.

David started working at Hintzsche Fertilizer, Inc. as a Second-shift Feed Mill Operator while attending Waubonsee Community College. After two years of college, he became a custom operator, then Troxel Plant Manager. In 1979, David became the Agronomy Division Manager for 11 years, moving his way up in the organization to the General Manager. In 1995, he became the President and Chief Executive Officer. He led the family owned business for 19 years before it was sold in 2014.

David was on several board affiliations including: Hintzsche Companies from 1990 to 2014, Premier Crop Systems from 2000 to 2007 and joined the board again in 2014. He was also on the board at DeKalb County Economic Development Corporation from 2005 to 2013, and United Suppliers and Agricultural Retailers Associations from 2011 to 2014. He was a Vistage (CEO peer group) member from 2002 to 2014 and recently joined the Willard Agri-Service Board of Directors at the beginning 2015.

Kelly Hintzsche

Kelly Hintzsche


My law practice is focused in the areas of business and corporate transactions; estate planning and administration; and residential and commercial real estate. I have advised corporate clients on various formation and governance matters, in addition to handling estate planning and probate and trust administrations. My commercial real estate practice includes property development, economic incentives and zoning matters. My residential real estate practice includes preparing real estate contracts and assisting clients throughout the closing process. 

I have also represented municipalities in the formation and administration of tax increment financing districts and other municipal financing mechanisms in addition to serving as general counsel on day-to-day governance matters. 

I received my J.D. from Northern Illinois University College of Law in 2008 and prior to that earned a B.S. degree in Criminal Justice at Illinois State University in 2005. 


PherDal Fertility Science, Inc.
Dec 20, 2022
$10k - $1.07M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives & Bonuses*


PherDal Phamily Bonus

Invest within the first week and receive 15% bonus shares

PherDal PhrienDs & Phamily Bonus

Invest within the first 15 days and receive 10% bonus shares

PherDal Early-testers Bonus

Invest within the first 30 days and receive 5% bonus shares



LinkedIn Investor Community


LinkedIn Investor Community 

SWAG (1 item)


LinkedIn Investor Community

SWAG (2 items )

Exclusive Investor App - Bronze Tier


5% bonus shares

LinkedIn Investor Community

SWAG (3 items )

Exclusive Investor App - Silver Tier

5% Discount code


7% bonus shares

LinkedIn Investor Community

SWAG (4 items )

Exclusive Investor App - Gold Tier

10% Discount code

1 hours of consulting/support from Dr. Jenn via virtual meetings  


10% bonus shares

LinkedIn Investor Community

SWAG (5 items )

Exclusive Investor App - Platinum Tier

15% Discount code

3 hours of 1:1 consulting/support with Dr. Jenn via virtual meetings

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

PherDal will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.87 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $187. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.


Article Image
Infertility! Girl, Let’s Talk! With Jennifer Hintzsche |98

Have you been struggling with infertility? How many people do you know that are on that same boat? Is there hope for you if IUI is financially out of reach? Meet Jennifer Hintzsche, inventor of the PherDal Kit

Article Image
Episode 35: At Home Insemination, with PherDal Kit Founder, Dr. Jenn

In this episode, I spoke to Dr. Jenn a Ph.D. doctor that shared her medical story and the device she invented to help her conceive.

Article Image

Cedar Rapids couple struggling with infertility has baby with help of new device

Article Image

Iowa couple struggling with infertility has baby with help of new device

Article Image
A Labor of Love and Science.

When a Dixon couple struggled to conceive a child, they came up with their own brainchild to help them have a baby, and now they are helping others too. Jennifer Westphal is one determined woman.



PherDal's Campaign ends today.

This is it. 

We've given it our all. 

Thank you for the support investors we can't wait to make you proud.  



This is the last chance!

This won't happen again. 

Invest before it's gone. 


PherDal is almost done - 48 HOURS AND IT'S GONE!


Don’t miss this - 3 Days left! Over $500K Invested!

Thank you for helping us hit $500K! This is the last 3 days before our campaign is over.



Announcing PherDal Baby #27!! 4 Days left!

OMGOODNESS ❤️ My heart is exploding!! 

I just learned about baby number 27 ❤️!! I can't tell you how much it means to me that these families share their stories and journey with me!

From the new mama: 

"I wanted to reach out and add a baby to the list! We purchased two Pherdal kits-one in November 2021 and the other in December 2021. We found out we were pregnant in January of this year, and our baby boy was born in September. We are so grateful for your product. I hadn’t even known about it as an option and thought we would have to have expensive and lengthy IUI or IVF procedures. Thanks to google, I found Pherdal and figured we had nothing to lose and tried it. I’m so thankful Pherdal existed at that time because it worked for us! Also, I really appreciated that there were three syringes per kit and that there was information/support included via downloadable guides as well. It made the whole process easier and less stressful for us!"

We need your help to give even more families this same beautiful gift. Invest now!! 


PherDal is officially PATENTED! 🥳 5 Days to go!

Last week Dr. Jenn received the official letter 

that PherDal is PATENTED!! 

Invest in our PATENTED medical device today!


Molly Hopkins shares PherDal's Story - 6 Days left

Thank you Molly Hopkins of LiviRae Lingerie & 90 Day Fiance for sharing our message!



ABC News Features PherDal - 7 days left to join

Check out the news from @WQAD that aired this week!

Join our mission, 

before it's too late.

Invest now!


10 days until it's gone.

You don't want to miss this opportunity.  

We are creating lives.

Invest now before it's over.


With less than 2 weeks - how can we get your support?

Read the latest press about our campaign! 

You can read the full article here.


Please share our message so we can help build more families! 

Invest now!

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into PherDal Fertility Science, Inc..



Patrick Krouse


6 months ago

Whom is the patent Assignee? I wasn't able to find the pending-patent using "PherDal" or "Hintzsche".



Alan Jacobson

6 months ago

Hi Dr. Jenn, I really like what you are doing and have a personal connection to your mission. I'm also looking for the answer to what others have asked, but I want to ask differently: You answered a question about your differentiators as follows: "First, we believe we are the only sterile, patent-pending, at-home intracervical insemination kit. Second, we have set a goal to become the first FDA-cleared, over-the-counter ICI kit on the market." Since I am not in the industry I cannot translate that into why you would end up being successful (not doubting, just wanting to understand). Why would you gain more consumers in the short run and be a potential acquisition target in the longer run because of these two advantages? Thanks!



James Pond

7 months ago

FDA clearance states “Class II and Class I medical devices are usually "cleared" by the FDA, which means the manufacturer can demonstrate that their product is "substantially equivalent to another (similar) legally marketed device" that already has FDA clearance or approval.” With that, my question is how is being “substantially equivalent” a marketable position of value?



Jan Camar

7 months ago

I have a question concerning production cost which is indicated as USD 140,000 for USD 3,333 units. Is this for the first 3,333 units you will get produced so including molding cost, research cost, shipping cost to your warehouse etc or will this be the price long terme? How many samples are you planning to get in stock at first once launching your shop? Will you produce products in China?Could there be any problems as production will not be in the US?



Jan Camar

7 months ago

Interesting product and market! Can you elaborate on your revenue of USD 25100 in 2021? Was this due tu a first trial of sales for your product? How many units did you sell and at what price? How much did you spend on marketing related to those sales and what marketing channels did you use? Did you continue sales in 2022 and if so could you provide the same information for 2022? Is fertijoy a competitor as well?



Vanessa Loveless

7 months ago

Do you have any additional information on forecasted revenue and gross profit for the next three years? Or any forecasted operational expenses for the next three years?



Maren Carron

7 months ago

Could you please provide more information on your unit economics (e.g. LTV/CAC)?



Marisa Adam

10 months ago

If I invest on two separate occasions, but reach the total amount for certain perks, do I still qualify for them?



Idalis Calderon

10 months ago

Love the product. I worry I will struggle with infertility, so I find this super interesting! I dove into the other comments about Mosie Baby, then all of your replies and each of the links you provided. Latoya and Anne, your comments appear to be inaccurate, but I wanted to ask a few more questions to make sure I understand. Mosie Baby’s kit is not FDA-cleared. They are registered as a developer of a non-dental general hospital syringe. Doesn’t that mean they can’t be used OTC? If true, why is CVS selling them? To Anne’s point- can’t you just register like them? Mosie Baby is not sterile, but its packaging makes it look sterile. I do like that you are sterile, and I read the article you referenced. It seems that you might be doing it first, but I would assume others will follow. Is any part of this protected under your patent? Mosie Baby also lists a survey at, but Latoya, is this the “clinical” research you are referring to? Mosie Baby did a survey of their success rate compared to IUI. However, to be included, the person MUST have gotten pregnant with Mosie Baby. So it seems to me that Mosie Baby took the number of all successes and failures of IUIs and compared it to ONLY people who got pregnant from them within 2-8 months after they purchased their kit? Is this correct? Dr. Jenn, is this the type of “clinical” research PherDal plans on doing too?





10 months ago

Very disaapointed that you elected not to provide a direct response to Brian's important question. FDA clearance is not required in this area as is evidenced by Mosie Baby. This means there is a very low barrier to entry by other competititors. I still do not see why your product is better than Mosie Baby. It seems that the central theme to your pitch is that it helped you get pregnant. Do you have any data which indicates that your product is better than Mosie Baby, , which already has material traction in the market?




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.